Climb Total Current Liabilities from 2010 to 2024
| CLYM Stock | 1.95 0.08 3.94% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 2.8 M | Current Value 3.6 M | Quarterly Volatility 1.1 M |
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 16.1 M, Total Revenue of 0.0 or Research Development of 20.4 M, as well as many indicators such as . Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
Climb | Total Current Liabilities |
Latest Climb Bio's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Climb Bio over the last few years. Total Current Liabilities is an item on Climb Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Climb Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Climb Bio's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Climb Bio's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Climb Total Current Liabilities Regression Statistics
| Arithmetic Mean | 3,483,920 | |
| Geometric Mean | 3,374,038 | |
| Coefficient Of Variation | 30.40 | |
| Mean Deviation | 704,139 | |
| Median | 3,063,000 | |
| Standard Deviation | 1,059,077 | |
| Sample Variance | 1.1T | |
| Range | 3.3M | |
| R-Value | 0.44 | |
| Mean Square Error | 969.6B | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | 105,195 | |
| Total Sum of Squares | 15.7T |
Climb Total Current Liabilities History
About Climb Bio Financial Statements
Climb Bio investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 2.8 M | 3.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Climb Bio Correlation against competitors. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.